Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.52
SQNM's Cash to Debt is ranked higher than
53% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. SQNM: 0.52 )
SQNM' s 10-Year Cash to Debt Range
Min: 0.41   Max: No Debt
Current: 0.52

Equity to Asset -0.39
SQNM's Equity to Asset is ranked higher than
51% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SQNM: -0.39 )
SQNM' s 10-Year Equity to Asset Range
Min: -0.48   Max: 0.96
Current: -0.39

-0.48
0.96
F-Score: 4
Z-Score: -8.90
M-Score: -2.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -24.02
SQNM's Operating margin (%) is ranked higher than
79% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. SQNM: -24.02 )
SQNM' s 10-Year Operating margin (%) Range
Min: -11450   Max: -55.06
Current: -24.02

-11450
-55.06
Net-margin (%) -18.13
SQNM's Net-margin (%) is ranked higher than
79% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. SQNM: -18.13 )
SQNM' s 10-Year Net-margin (%) Range
Min: -10900   Max: -53.61
Current: -18.13

-10900
-53.61
ROE (%) -14282.71
SQNM's ROE (%) is ranked lower than
52% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. SQNM: -14282.71 )
SQNM' s 10-Year ROE (%) Range
Min: -14282.71   Max: -27.62
Current: -14282.71

-14282.71
-27.62
ROA (%) -25.89
SQNM's ROA (%) is ranked higher than
75% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. SQNM: -25.89 )
SQNM' s 10-Year ROA (%) Range
Min: -92.63   Max: -23.97
Current: -25.89

-92.63
-23.97
ROC (Joel Greenblatt) (%) -207.50
SQNM's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. SQNM: -207.50 )
SQNM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -897.73   Max: -244.94
Current: -207.5

-897.73
-244.94
Revenue Growth (3Y)(%) 28.80
SQNM's Revenue Growth (3Y)(%) is ranked higher than
92% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. SQNM: 28.80 )
SQNM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -20.6   Max: 293.1
Current: 28.8

-20.6
293.1
EBITDA Growth (3Y)(%) -23.50
SQNM's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. SQNM: -23.50 )
SQNM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -57.8   Max: 45.7
Current: -23.5

-57.8
45.7
EPS Growth (3Y)(%) -18.10
SQNM's EPS Growth (3Y)(%) is ranked higher than
70% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. SQNM: -18.10 )
SQNM' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.3   Max: 43.7
Current: -18.1

-59.3
43.7
» SQNM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SQNM Guru Trades in Q4 2013

Chuck Royce Sold Out
Steven Cohen Sold Out
» More
Q1 2014

SQNM Guru Trades in Q1 2014

Jim Simons 693,351 sh (New)
» More
Q2 2014

SQNM Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q4 2014

SQNM Guru Trades in Q4 2014

Jim Simons 34,240 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SQNM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 13.11
SQNM's Forward P/E is ranked higher than
98% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SQNM: 13.11 )
N/A
P/S 2.20
SQNM's P/S is ranked higher than
96% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. SQNM: 2.20 )
SQNM' s 10-Year P/S Range
Min: 0.99   Max: 29.2
Current: 2.2

0.99
29.2
EV-to-EBIT -10.47
SQNM's EV-to-EBIT is ranked higher than
58% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SQNM: -10.47 )
SQNM' s 10-Year EV-to-EBIT Range
Min: -42.5   Max: 0.1
Current: -10.47

-42.5
0.1
Current Ratio 1.73
SQNM's Current Ratio is ranked higher than
59% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. SQNM: 1.73 )
SQNM' s 10-Year Current Ratio Range
Min: 1.15   Max: 26.12
Current: 1.73

1.15
26.12
Quick Ratio 1.61
SQNM's Quick Ratio is ranked higher than
60% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. SQNM: 1.61 )
SQNM' s 10-Year Quick Ratio Range
Min: 0.94   Max: 26.03
Current: 1.61

0.94
26.03
Days Inventory 41.65
SQNM's Days Inventory is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SQNM: 41.65 )
SQNM' s 10-Year Days Inventory Range
Min: 19.21   Max: 271.27
Current: 41.65

19.21
271.27
Days Sales Outstanding 12.06
SQNM's Days Sales Outstanding is ranked higher than
96% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. SQNM: 12.06 )
SQNM' s 10-Year Days Sales Outstanding Range
Min: 23.03   Max: 182.5
Current: 12.06

23.03
182.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.44
SQNM's Price/Median PS Value is ranked higher than
96% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. SQNM: 0.44 )
SQNM' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 36.7
Current: 0.44

0.23
36.7
Earnings Yield (Greenblatt) -9.50
SQNM's Earnings Yield (Greenblatt) is ranked higher than
67% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SQNM: -9.50 )
SQNM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.3   Max: 6889
Current: -9.5

-10.3
6889

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QNMA.Germany,
Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life sciences company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.
» More Articles for SQNM

Headlines

Articles On GuruFocus.com
GuruFocus 5-year lows: Anworth Mortgage Asset Corporation, Contango Oil & Gas Company, Dendreon Corp Sep 29 2013 
Weekly Three-Year Low Highlights: NS, MCRL, TITN, SQNM Sep 24 2013 
5 Year Lows: Anworth Mortgage Asset Corporation, Cantago Oil & Gas Company, Sequenom and North Ameri Sep 22 2013 
Gurus Hold Five-Year Lows in Biotech, Utilities Sep 20 2013 
3.31 Mar 12 2013 
Weekly CFO Buys Highlight: PTSX, MTG, IRDM, SQNM, FNFG, LF Aug 13 2012 
Sequenom Inc. CEO Harry Hixson Bought 50,000 Shares Aug 03 2012 
Sequenom Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sequenom Inc. Reports Operating Results (10-Q) May 07 2010 
Sequenom Inc. Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
Wedbush Securities Expects In-Line Results For Sequenom Feb 26 2015
Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2014 Financial Results And Conference... Feb 19 2015
SEQUENOM INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 23 2015
Cypher Genomics and Sequenom Announce Development Agreement Jan 22 2015
Cypher Genomics and Sequenom Announce Development Agreement Jan 22 2015
SEQUENOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 12 2015
Sequenom, Inc. Announces Participation At The 33rd Annual J.P. Morgan Healthcare Conference Jan 06 2015
Sequenom, Inc. Announces Participation At The 33rd Annual J.P. Morgan Healthcare Conference Jan 06 2015
SEQUENOM INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 23 2014
SEQUENOM INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Dec 05 2014
Sequenom (SQNM) Shares March Higher, Can It Continue? Dec 04 2014
Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% Dec 04 2014
Record territory again for the Dow Industrials Dec 03 2014
Sequenom (SQNM) Stock Spikes Following NIPT Patent Settlement With Illumina Dec 03 2014
Sequenom climbs as Illumina patent dispute ends Dec 03 2014
Sequenom climbs as Illumina patent dispute ends Dec 03 2014
Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding... Dec 03 2014
Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding... Dec 03 2014
Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding... Dec 03 2014
Sequenom, Inc. Announces Participation At The 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK